Medsafe Of New Zealand Cites U.S. FDA In Safety Defense Of Pradaxa
This article was originally published in PharmAsia News
New Zealand's regulatory agency Medsafe sought to defend itself against safety questions raised over its approval of Boehringer Ingelheim's Pradaxa (dabigatran) for preventing blood clots in surgery by noting that it had access to the same clinical trial data required by U.S. FDA, which also approved the drug
You may also be interested in...
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Early Research Suggests Wearables Can Spot Early Signs Of COVID-19; Fitbit Receives $2.5m Army Award
A consortium of researchers, including Fitbit, are developing algorithms to spot COVID-19 before people become ill.